Report: More than half of the world's population will be overweight/obese by 2035

Published Date: 08 Mar 2023

The World Health Organization's 2023 Atlas predicts that 51% of the world's population, or more than 4 billion people, will be overweight or obese within the next 12 years.

Read Full News

Latest News

GLP-1 Boom Nudges Cannabis Dispensaries to Rethink Offerings

The surging popularity of GLP-1 weight-loss drugs is quietly reshaping the $40 billion U.S. cannabis market, experts and industry executives said, as retailers ⁠adjust...

Evidence Grows for Weight Loss Reducing Cancer Risk

With studies showing that the increased cancer risk linked to obesity can be reduced with weight loss, experts call for greater awareness.

The Science of piRNA and Predicting Death With a Blood Test

A new study analyzed piRNA — first discovered in 2006 — as a strong predictor of short-term survival in older patients. It could one day be a simple blood test.

Air Pollution’s Toll on Bone Health

Research links air pollution and heavy metals to accelerated bone loss and higher fracture rates, driven by systemic inflammation, oxidative stress, and endocrine disruption.

Combining Insulin Pump, CGM Into One Device Appears Feasible

Early proof-of-concept study showed that a patch pump with integrated glucose sensing at the site of insulin delivery can function in people with type 1 diabetes.

PCOS Linked to Later Menopause and Fewer Symptoms

A population-based study reveals that women with PCOS are less likely to reach late perimenopause or postmenopause by their mid-40s than their peers and experience fewer menopausal symptoms.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

The surging popularity of GLP-1 weight-loss drugs is quietly reshaping the $40 billion U.S. cannabis market, experts and industry executives said, as retailers ⁠adjust...

With studies showing that the increased cancer risk linked to obesity can be reduced with weight loss, experts call for greater awareness.

A new study analyzed piRNA — first discovered in 2006 — as a strong predictor of short-term survival in older patients. It could one day be a simple blood test.

Research links air pollution and heavy metals to accelerated bone loss and higher fracture rates, driven by systemic inflammation, oxidative stress, and endocrine disruption.

Early proof-of-concept study showed that a patch pump with integrated glucose sensing at the site of insulin delivery can function in people with type 1 diabetes.

A population-based study reveals that women with PCOS are less likely to reach late perimenopause or postmenopause by their mid-40s than their peers and experience fewer menopausal symptoms.

News All Time

Intensive Lifestyle Intervention Boosts QOL in Obesity

Greater weight loss during a 24-month primary care lifestyle intervention was associated with larger improvements in quality-of-life among patients with obesity.

Lilly's Obesity Pill Draws 1,390 US Prescriptions in Launch Week

Eli Lilly's newly launched weight-loss pill was prescribed 1,390 times in the U.S. in its first week of sales, according to analysts who cited IQVIA data, ⁠indicating that...

Upcoming AACE Meeting Theme in Las Vegas: ‘Viva Nutrition!’

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 will also feature topics such as AI, preventing type 1 diabetes, and thyroid disease management.

Meal Patterns Matter for Better Sleep and Quality of Life

More frequent and irregular meals are linked to poor sleep and lower quality of life, and a longer interval between the last meal and bedtime may improve sleep quality and mental and physical health.

Rise of Early Onset Diabetes a Looming Crisis

More and more patients are developing type 2 diabetes while still young. The diagnosis may lead to a life of disease.

Chronic Pancreatitis: Algorithm-Based Care Matches Standard

An evidence-based management algorithm does not improve quality of life or pain severity compared with standard care among patients with chronic pancreatitis.

Remote Monitoring Cuts Infection Hospitalizations

Researchers compared outcomes in adults with hematologic malignancies receiving anticancer therapy who were enrolled in an ePRO-based RTM platform with those who were not.

Managing Care When Gender-Affirming Therapy Is Limited

As access to gender-affirming care for minors narrows, clinicians are adapting — using nonhormonal options, stronger mental health support, and creative, patient-centered strategies.

Reddit Analysis Uncovers Unreported GLP-1 Side Effects

Reproductive symptoms, temperature-related complaints, and psychiatric symptoms are among the side effects of GLP-1s reported on social media.

Postmenopausal HRT Tied to Glaucoma Risk in Women

The use of postmenopausal hormone replacement therapy is associated with an increased risk for glaucoma in Finnish women aged 50 years or older, according to a recent nested case-control study.

Novo Nordisk Launches Wegovy Subscription Program

The telehealth platform program saves money for some self-pay patients, but experts express concerns about fragmentation of care.

Incretin-Based Drugs Show Superior Glycemic Profiles on CGM

Continuous glucose monitoring in the GRADE trial shows that incretin-based drugs such as sitagliptin and liraglutide produce the most stable glycemic profiles and show the lowest hypoglycemia risk.

Recent Depression Tied to Treatment Intensification in T2D

Patients with T2D who have a history of depression, especially a recent episode, are more likely to undergo earlier treatment intensification and insulin initiation than those who do not.

US FDA Weighs Broader Use Of Testosterone Therapy for Low Sex Drive in Men

The U.S. Food and Drug Administration is considering approving testosterone replacement therapy ⁠to treat low sex drive in men whose bodies do not produce enough of ⁠the...

Tirzepatide Best for Weight Loss in Adults Without T2D

High doses of the dual agonist tirzepatide appear to provide greater weight loss than other GLP-1s among adults with overweight or obesity who don’t have type 2 diabetes.

Can Genes Affect GLP-1 Side Effects and Treatment Outcomes?

Two genetic variants may help explain differences in side effects and weight loss in patients taking GLP-1 drugs.

Recommended News For You

A paper strip test might enable the early detection of cancer.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

No Solace From Drug Scarcities; Novel Guidelines Regarding Lymphedema; A "Good" Patient Is Forgotten.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.

Obesity-related cancer rising among both younger and older adults worldwide, study finds

Recommended Articles For You

Interplay of Brown Hair, Follicular Biology, and Hair Growth Inhibitors in Melanoma Pathogenesis 

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy 

Real-World Evidence and Patient Voices: Redefining Outcomes in Modern Oncology 

Understanding Epoetin and Its Role in Treating Chronic Kidney Disease  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer care crowdfunding increasingly common, but rarely successful

2.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

3.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

4.

Firefighters who eat better can combat cancer.

5.

X-ray and radar technology combined to reduce cancer screening risks

1.

What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder

2.

Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy

3.

Lymphomatoid Papulosis: What You Need to Know

4.

A New Perspective on Spherocytosis: Uncovering Innovative Treatments

5.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

3.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

4.

Updates on the First Line Management of ALK+ NSCLC

5.

An In-Depth Look At The Signs And Symptoms Of Lymphoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot